RETROSPECTIVE ANALYSIS OF CAD IN TYPE2 DM PATIENTS AND RISK SCORING OF CAD BY DIFFERENT MODALITIES USED
Not Applicable
- Conditions
- Health Condition 1: E085- Diabetes mellitus due to underlying condition with circulatory complications
- Registration Number
- CTRI/2022/11/047117
- Lead Sponsor
- DY Patil Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Type 2 diabetes with history of CAD
2.Type 2 diabetes with compliants of chest pain
3.Type2 diabetes patients with pre-existing CVD
4.Type 2 diabetes patients with normal coronary arteries
Exclusion Criteria
1. Pregnancy or lactating mother
2.Population below 18 years
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To Stratify the risk of CAD in TYPE2 DM patientsTimepoint: Within 4-6 weeks
- Secondary Outcome Measures
Name Time Method To assess sugar profile,to determine lipid profile,to compare and correlate clinical lab findings with CAD reports.Timepoint: 1 year
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link Type 2 Diabetes mellitus to coronary artery disease in patients with circulatory complications?
How does the risk scoring of coronary artery disease in Type 2 Diabetes mellitus patients compare with standard-of-care diagnostic methods?
What biomarkers are most effective for predicting significant coronary artery disease in Type 2 Diabetes mellitus patients with circulatory complications?
What adverse events are associated with coronary artery disease risk stratification in Type 2 Diabetes mellitus patients and how can they be managed?
Are there any novel therapeutic compounds or combination approaches that could improve coronary artery disease outcomes in Type 2 Diabetes mellitus patients with circulatory complications?